文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

粪便微生物群移植的封装方案。

Encapsulation protocol for fecal microbiota transplantation.

机构信息

1st Department of Internal Medicine - Department of Infectology, University of Pécs Clinical Centre, Pécs, Hungary.

Department of Medical Microbiology and Immunology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.

出版信息

Front Cell Infect Microbiol. 2024 Jun 26;14:1424376. doi: 10.3389/fcimb.2024.1424376. eCollection 2024.

DOI:10.3389/fcimb.2024.1424376
PMID:38988813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11233434/
Abstract

INTRODUCTION: infections (CDI) continue to pose a challenge for clinicians. Fecal microbiota transplantation (FMT) is an effective treatment option in CDI. Furthermore, recent and ongoing studies suggest potential benefits of FMT in other diseases as well. METHODS: We would like to present a novel protocol for encapsulation of lyophilized fecal material. Our method provides with better compliance as well as improved flexibility, storage and safety. RESULTS: FMT was conducted in 28 patients with an overall success rate of 82,14% using apsules containing lyophilized stool. 16 of patients were given capsules with lessened bacteria counts. The success rate in this group was 93,75%. DISCUSSION: The results highlight the still unanswered questions about the mechanism of action and contribute to a wider use of FMT in the clinical praxis and in research.

摘要

介绍：感染（CDI）仍然对临床医生构成挑战。粪便微生物群移植（FMT）是 CDI 的一种有效治疗选择。此外，最近和正在进行的研究表明，FMT 在其他疾病中也具有潜在的益处。

方法：我们想提出一种新的冷冻干燥粪便材料包封方案。我们的方法具有更好的顺应性以及更高的灵活性、存储和安全性。

结果：使用含有冻干粪便的胶囊进行了 28 例患者的 FMT，总体成功率为 82.14%。其中 16 例患者给予细菌计数减少的胶囊，成功率为 93.75%。

讨论：这些结果强调了关于作用机制的一些尚未解决的问题，并有助于更广泛地将 FMT 应用于临床实践和研究中。

相似文献

[1]
Encapsulation protocol for fecal microbiota transplantation.

Front Cell Infect Microbiol. 2024

[2]
Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules.

J Hosp Infect. 2020-6

[3]
Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.

PLoS One. 2018-11-2

[4]
Efficacy of lyophilised bacteria-rich faecal sediment and supernatant with reduced bacterial count for treating patients with Infection - A novel method for capsule faecal microbiota transfer.

Front Cell Infect Microbiol. 2023

[5]
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).

Cochrane Database Syst Rev. 2023-4-25

[6]
Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis?

Diagn Microbiol Infect Dis. 2017-8

[7]
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection.

BMC Med. 2016-9-9

[8]
Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study.

Am J Gastroenterol. 2017-6

[9]
Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.

mSphere. 2021-10-27

[10]
Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.

Ann Intern Med. 2016-11-1

引用本文的文献

[1]
Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection.

Pathogens. 2024-11-21

本文引用的文献

[1]
Efficacy of lyophilised bacteria-rich faecal sediment and supernatant with reduced bacterial count for treating patients with Infection - A novel method for capsule faecal microbiota transfer.

Front Cell Infect Microbiol. 2023

[2]
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.

Drugs. 2022-10

[3]
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.

BMC Infect Dis. 2022-3-12

[4]
A Novel Bacteriophage with Broad Host Range against Clostridioides difficile Ribotype 078 Supports SlpA as the Likely Phage Receptor.

Microbiol Spectr. 2022-2-23

[5]
SER-109, an Oral Microbiome Therapy for Recurrent Infection.

N Engl J Med. 2022-1-20

[6]
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.

Clin Microbiol Infect. 2021-12

[7]
Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study.

BMC Gastroenterol. 2021-7-8

[8]
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.

Clin Infect Dis. 2021-9-7

[9]
How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods.

Front Cell Infect Microbiol. 2021

[10]
Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.

Clin Microbiol Infect. 2021-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索